Draminju

Adult dosage

Administer intravenously by drip at a maximum dosage of 1.5 g of total amino acids per kg of body weight per day (equivalent to 2100 mL per day for a 70 kg weight). Administration rate: 1.7 to 2.1 mL per kg of body weight over 60 minutes (equivalent to 40 to 50 drops per minute for a 70 kg weight).

This medication should be used strictly according to the doctor's instructions and should not be taken or stopped arbitrarily. Patients with severe renal dysfunction or elevated blood nitrogen levels should not be administered this medication. It is also safe not to administer this drug to patients with metabolic disorders affecting nitrogen utilization, severe heart failure, or pulmonary edema. Patients with very low or no urine output, those with elevated sodium and chloride levels, or those with alkalotic blood should avoid this medication due to certain components. If magnesium ions are included, it should not be used in patients with issues in cardiac electrical signal transmission or severe myasthenia gravis. It should also be avoided in patients with excessive water supply in the body or those with a history of myocardial infarction. Caution is required for patients with severe acidosis, congestive heart failure, or heart failure, and careful administration is required for patients with abnormal sodium or potassium levels, as certain components may trigger allergic reactions or asthmatic attacks. Rarely, hypersensitivity reactions such as skin rashes may occur, and gastrointestinal symptoms such as nausea or vomiting may also be experienced. Cardiac-related symptoms include discomfort in the chest, palpitations, rapid heartbeat, and elevated blood pressure. Rapid administration of large volumes may lead to metabolic acidosis due to acidification of the body. Additionally, chills, fever, headache, difficulty breathing, shock, bronchospasms, and urinary spasms may occur. If magnesium ions are included, peripheral vessels may dilate, causing a drop in blood pressure. Various metabolic abnormalities can occur, such as metabolic acidosis, hypophosphatemia, alkalosis, blood sugar abnormalities, dehydration, hypoglycemia, increased liver enzymes, vitamin imbalances, and electrolyte imbalances. Patients with weak liver or kidney function may experience elevated blood urea nitrogen levels, and those with severely impaired liver function may develop serious metabolic abnormalities leading to coma. When administering large doses of this drug or using it with other electrolyte-containing drugs, careful monitoring of the electrolyte balance is necessary. Overdose may lead to metabolic alkalosis, especially when using preparations with acetate ions. Patients with kidney, lung, or heart diseases should be cautious to avoid excessive water supply in the body. Diabetic patients should frequently measure and manage blood sugar levels during treatment with this drug. Patients with hyponatremia or impaired liver or kidney function need to carefully manage dosage and their fluid and electrolyte status. Interactions with other medications should also be approached cautiously; for example, using this medication with tetracycline antibiotics may reduce protein-sparing effects. If magnesium ions are included, caution is needed as precipitates may occur when administered with calcium preparations. The safety for pregnant women has not been established, so it should only be used cautiously in cases where the therapeutic benefit outweighs the risks. Children are at risk for hyperammonemia due to immature hepatic function, so concentrations should be kept low, and blood ammonia levels should be monitored frequently. Older adults require caution as bodily functions may be impaired, necessitating slower administration rates and dosage adjustments. When administering, special attention must be paid to electrolyte balance based on whether it contains electrolytes, and rapid intravenous administration may lead to chills or vomiting, so it should be given slowly. This medication must always be stored at an appropriate temperature, with strict maintenance of aseptic conditions during preparation and administration, and discolored or turbid solutions should not be used. Additionally, the solution should be used promptly after mixing and must be used within 24 hours if refrigerated, and if crystallization occurs, it should be appropriately reheated to dissolve. This medication must not be used if the packaging or container is damaged or has deteriorated.

Serious side effects

Rash (hypersensitivity), difficulty breathing, respiratory arrest, shock, bronchospasm, liver failure, kidney failure, severe edema accompanied by elevated blood pressure (risk in renal failure, pulmonary edema, heart failure patients).

Mild side effects

• Nausea
• vomiting
• chest discomfort
• palpitations
• rapid heart rate (tachycardia)
• elevated blood pressure
• chills
• fever
• headache
• urinary spasm

This medication should be stored in a sealed container to prevent air or moisture from entering, and the storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the medication can be safely maintained.

Appearance

A transparent solution that is colorless to pale yellow contained in a polypropylene aqueous injection container.

Package unit

100mL/bag, 200mL/bag, 250mL/bag